First patients dosed in Phase III trials evaluating Fasenra in hypereosinophilic syndrome ...

Retrieved on: 2020-12-16 18:00:00

Tags for this article:

Medical specialties

Clinical medicine

Organ systems

Monoclonal antibodies

Orphan drugs

Immune system disorders

Respiratory therapy

Immunosuppressants

Mepolizumab

Eosinophilic granulomatosis with polyangiitis

Eosinophilic esophagitis

Asthma

AstraZeneca plc

Click the tags to see associated articles and topics

First patients dosed in Phase III trials evaluating Fasenra in hypereosinophilic syndrome .... View article details on hiswai:

Excerpt

<b>AstraZeneca's</b> ambition in immunology is to achieve disease control and ultimately clinical remission in targeted immune-driven diseases. <b>AstraZeneca</b>.

Article found on: www.pharmiweb.com

View Original Article